Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)

China flag China · Delayed Price · Currency is CNY
31.20
+0.13 (0.42%)
At close: May 12, 2026
Market Cap11.44B +9.1%
Revenue (ttm)277.82M +452.9%
Net Income-564.33M
EPS-1.54
Shares Out366.68M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,932,420
Average Volume4,817,326
Open30.82
Previous Close31.07
Day's Range30.63 - 31.81
52-Week Range23.67 - 37.88
Beta0.72
RSI58.61
Earnings DateApr 30, 2026

About SHA:688443

Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a mo... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 793
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688443
Full Company Profile

Financial Performance

In 2025, SHA:688443's revenue was 230.73 million, an increase of 666.66% compared to the previous year's 30.09 million. Losses were -535.65 million, -32.81% less than in 2024.

Financial Statements